Where Wegovy is produced and how it reaches UK patients

Where semaglutide is actually made

Novo Nordisk operates one of the world's largest biopharmaceutical production networks. The active ingredient in Wegovy, semaglutide, is a GLP-1 receptor agonist, a peptide molecule synthesised through a complex fermentation and chemical modification process, not extracted from a natural source. Primary manufacturing, where the molecule itself is produced and purified, has historically been centred in Denmark, at sites including Novo Nordisk's Kalundborg facility, which is one of the largest insulin and GLP-1 production plants in the world. Secondary manufacturing (filling the pre-filled pens) also takes place across multiple international sites.

Novo Nordisk has invested heavily in expanding capacity since global demand for semaglutide outstripped supply from around 2022. New production lines in Denmark and the US have been commissioned, and the company has announced multi-billion-dollar commitments to further expansion. That context matters, because supply shortages have been real, and shortages create the conditions in which counterfeit or illicitly traded products appear.

For a deeper look at who sits behind the medicine, the full profile of who produces Wegovy covers Novo Nordisk's corporate structure and UK regulatory relationships in more detail.

The journey from factory to UK pharmacy shelf

If you are curious about where Wegovy is from and how its country of origin fits into the supply chain, knowing where it is produced is only part of the picture. What matters for a UK patient is the chain of custody after it leaves the factory. In the UK, an imported medicine must be released by a Qualified Person at a licensed manufacturer or importer before it can be distributed. It then moves through a wholesale dealer holding a Wholesale Dealer's Authorisation (WDA) and arrives at a GPhC-registered pharmacy, which dispenses it against a valid prescription.

This chain is what the MHRA regulates. It is also what counterfeiters exploit: fake pens are manufactured elsewhere, packaged to look authentic, and enter circulation outside this chain entirely, typically through social media sellers or unregistered websites. The MHRA has warned publicly about fake GLP-1 pens and has made large seizures of counterfeit stock, including an illicit UK manufacturing site producing fake tirzepatide pens that was raided in Northampton in October 2025.

You can check any online pharmacy's legitimacy on the GPhC's pharmacy register. If a seller cannot be found there, treat that as a firm stop signal. Suspect sellers can also be reported directly through the MHRA's Yellow Card scheme.

For more on buying safely, the guide to buying Wegovy online in the UK walks through the verification steps in full.

Does where it's produced affect how it works?

Semaglutide's mechanism is the same regardless of which Novo Nordisk facility made the batch. It works by activating GLP-1 receptors involved in appetite regulation and blood-sugar control, slowing gastric emptying and signalling fullness to the brain. The STEP 1 trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks at the 2.4 mg weekly dose, and those results reflect the pharmacology of semaglutide itself, not the geography of its production.

What the origin does affect is quality assurance. A pen released through the licensed UK chain has been batch-tested to confirm it contains what it says it contains, in the stated concentration, with no contamination. Counterfeit pens that have been analysed by the MHRA have included the wrong active substance entirely, in some cases insulin, which can be acutely dangerous. So the honest answer to anyone wondering whether it matters where their pen came from: the details of how and where Wegovy is produced, and by whom, matter enormously when it comes to the legitimate Novo Nordisk supply chain; the specific town on the factory floor matters very little.

The semaglutide overview page has more on how the molecule works and what clinical evidence supports its use for weight management.

Wegovy's UK licensing and what legitimacy looks like at the dispensing end

Wegovy holds a UK marketing authorisation for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. The NHS medicines page for semaglutide covers the licensed use, common side effects and storage requirements in plain terms and is worth a read before starting treatment.

For patients asking about this topic (and it is a question our prescribers hear, especially from people who have seen Wegovy offered cheaply on social media) the concern behind it is usually legitimate. You want to know the pen in your hands is real. That concern is well-founded, and the answer is not to research the factory address but to check the pharmacy against the GPhC register and confirm a prescriber assessed you before any medicine was issued.

If you are considering treatment, the Wegovy pillar page covers eligibility, the licensed dosing pathway and how private access works in the UK. For a broader look at your options, the weight-loss treatment overview sets out everything nume currently offers.

Consultations at nume are reviewed the same day by a GPhC-registered Independent Prescriber, a real clinician, not a decision algorithm. If clinically suitable, treatment is dispatched the same day for free next-working-day tracked delivery. Start your free consultation whenever you are ready.